Abstract
The paper presents the results of a study of the effect of L-lysine aescinate on the time course of changes in the clinical and laboratory parameters of patients with acute cerebrovascular accident in the presence of the novel coronavirus infection. L-lysine aescinate enhances the efficiency of the basic therapy, which is confirmed by more pronounced changes in the number of laboratory parameters, including coagulograms, inflammatory markers, and predictors for cardiovascular catastrophes, as well as by an improvement in neurological recovery. The study shows that L-lysine aescinate is well tolerated and there are no adverse reactions. A rationale is provided for the necessity of incorporating L-lysine aescinate in the treatment regimen as an angioprotective, decongestant, and neuroprotective agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
